BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cannabidiol (Epidiolex) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cannabidiol (Epidiolex)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06381791-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cannabidiol (Epidiolex): Phase 1/2 readout est. (NCT06381791)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1/2.\nStudy: CBD for Pain Follo
 wing Orthopedic Shoulder Surgery\nEstimated primary completion: 30 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-e
 pidiolex#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06381791
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462559-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cannabidiol (Epidiolex): Phase 1 readout est. (NCT07462559)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1.\nStudy: KF2025#1 Trial: Keta
 mine\, Cannabidiol and Cobicistat Interaction Study\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/cannabidiol-epidiolex#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07462559
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930703-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Cannabidiol (Epidiolex): Phase 1/2 readout est. (NCT06930703)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1/2.\nStudy: Cannabidiol in Sic
 kle Cell Disease\nEstimated primary completion: 1 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06930703
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918469-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Cannabidiol (Epidiolex): Phase 1 readout est. (NCT07918469)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1.\nStudy: A Clinical Study to 
 Assess the Safety\, Tolerability and Pharmacokinetics of Orally Administer
 ed Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Adults\nEsti
 mated primary completion: 15 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07918469
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04992624-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT04992624)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: Cannabinoid Interact
 ions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the 
 Knee\nEstimated primary completion: 22 March 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04992624
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333041-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cannabidiol (Epidiolex): Phase 2/3 readout est. (NCT06333041)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2/3.\nStudy: Study of Cannabidi
 ol in Sanfilippo Syndrome\nEstimated primary completion: April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06333041
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05649059-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cannabidiol (Epidiolex): Phase 4 readout est. (NCT05649059)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 4.\nStudy: Investigating the Ef
 fects of Cannabidiol on Social Anxiety Disorder\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cannab
 idiol-epidiolex#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05649059
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05044819-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Cannabidiol (Epidiolex): Phase 4 readout est. (NCT05044819)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 4\, Epilepsy.\nStudy: Assessmen
 t of Potential for Chronic Liver Injury in Participants Treated With Epidi
 olex (Cannabidiol) Oral Solution\nEstimated primary completion: 1 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epid
 iolex#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05044819
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123467-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cannabidiol (Epidiolex): Phase 3 readout est. (NCT07123467)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 3.\nStudy: Cannabidiol-Assisted
  Learning for Managing Generalized Anxiety Disorder\nEstimated primary com
 pletion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cannabidiol-epidiolex#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07123467
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233239-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Cannabidiol (Epidiolex): Phase 1 readout est. (NCT07233239)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1\, Epilepsy.\nStudy: A Study t
 o Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [G
 WP42003-P\, JZP926]) for the Treatment of Focal-Onset Seizures\nEstimated 
 primary completion: 29 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cannabidiol-epidiolex#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07233239
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886606-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cannabidiol (Epidiolex): Phase 1 readout est. (NCT07886606)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1.\nStudy: Cannabidiol in Opioi
 d Use Disorder and Chronic Pain With Buprenorphine\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cannabidiol-epidiolex#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07886606
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06924827-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Cannabidiol (Epidiolex): Phase 4 readout est. (NCT06924827)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 4\, Epilepsy.\nStudy: A Study t
 o Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD
 ) to Epidiolex\nEstimated primary completion: 1 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06924827
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731894-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280107
DTEND;VALUE=DATE:20280108
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT06731894)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: Phytocannabinoids fo
 r Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast an
 d Colon Cancer Survivors\nEstimated primary completion: 7 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06731
 894
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840899-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT06840899)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: CBD for Lower Urinar
 y Tract Dysfunction in Spinal Cord Injury\nEstimated primary completion: M
 ay 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-
 epidiolex#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06840899
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148206-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Cannabidiol (Epidiolex): Phase 3 readout est. (NCT07148206)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 3.\nStudy: Dronabinol and Epidi
 olex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation 
 Trial\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07148206
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778810-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT07778810)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: Epidiolex Trial for 
 Presymptomatic Treatment of Sturge-Weber Syndrome\nEstimated primary compl
 etion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/can
 nabidiol-epidiolex#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07778810
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06213233-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT06213233)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: MIVetsCan: Cannabidi
 ol (CBD)-Care Trial\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06213233
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728097-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20281228
DTEND;VALUE=DATE:20281229
SUMMARY:Cannabidiol (Epidiolex): Phase 4 readout est. (NCT07728097)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 4\, Epilepsy.\nStudy: A Study t
 o Investigate the Effect of Gradual Titration to Optimize Cannabidiol Trea
 tment in Adults With LGS\nEstimated primary completion: 28 December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiolex
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 28097
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06234631-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT06234631)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: Cannabidiol for Post
 operative Opioid Reduction in Primary Total Knee Arthroplasty\nEstimated p
 rimary completion: January 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cannabidiol-epidiolex#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06234631
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564245-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Cannabidiol (Epidiolex): Phase 2 readout est. (NCT07564245)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 2.\nStudy: Efficacy of Cannabid
 iol in the Management of Self-injuries in Children and Adolescents With Se
 vere Neurodevelopmental Disorders.\nEstimated primary completion: May 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epidiol
 ex#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7564245
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001930-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Cannabidiol (Epidiolex): Phase 1 readout est. (NCT07001930)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1.\nStudy: Effects of Cannabidi
 ol on Stress and Nicotine Withdrawal\nEstimated primary completion: 1 Sept
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cannabidi
 ol-epidiolex#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07001930
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07278505-7557@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Cannabidiol (Epidiolex): Phase 1/2 readout est. (NCT07278505)
DESCRIPTION:Cannabidiol (Epidiolex)\, phase 1/2.\nStudy: Study of Cannabidi
 ol and Neuroimaging on Stress\nEstimated primary completion: 28 February 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-epid
 iolex#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07278505
URL:https://assetmemo.bio/drug/cannabidiol-epidiolex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
